KR20090071603A - Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커 - Google Patents

Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커 Download PDF

Info

Publication number
KR20090071603A
KR20090071603A KR1020097007973A KR20097007973A KR20090071603A KR 20090071603 A KR20090071603 A KR 20090071603A KR 1020097007973 A KR1020097007973 A KR 1020097007973A KR 20097007973 A KR20097007973 A KR 20097007973A KR 20090071603 A KR20090071603 A KR 20090071603A
Authority
KR
South Korea
Prior art keywords
biomarkers
gene expression
patient
raf
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097007973A
Other languages
English (en)
Korean (ko)
Inventor
나타샤 에이지즈
에드워드 몰러
다린 스튜어트
칼라 하이즈
킴 아달렌
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20090071603A publication Critical patent/KR20090071603A/ko
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020097007973A 2006-09-19 2007-09-19 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커 Ceased KR20090071603A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84560106P 2006-09-19 2006-09-19
US60/845,601 2006-09-19

Publications (1)

Publication Number Publication Date
KR20090071603A true KR20090071603A (ko) 2009-07-01

Family

ID=39445772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007973A Ceased KR20090071603A (ko) 2006-09-19 2007-09-19 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커

Country Status (13)

Country Link
US (1) US20100004253A1 (enExample)
EP (1) EP2074226A2 (enExample)
JP (2) JP2010504530A (enExample)
KR (1) KR20090071603A (enExample)
CN (1) CN101541977A (enExample)
AU (1) AU2007340265B2 (enExample)
BR (1) BRPI0716944A2 (enExample)
CA (1) CA2662508A1 (enExample)
IL (1) IL197450A0 (enExample)
MX (1) MX2009002936A (enExample)
RU (1) RU2009114745A (enExample)
SG (1) SG174826A1 (enExample)
WO (1) WO2008082730A2 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
CA2728674A1 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
US12680139B2 (en) 2009-01-07 2026-07-14 Myriad Genetics, Inc. Cancer biomarkers
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
EP2444503B1 (en) * 2010-10-20 2016-03-02 Université Joseph Fourier Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method
US20130287805A1 (en) * 2010-10-21 2013-10-31 Yusuke Nakamura C18orf54 peptides and vaccines including the same
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
EP2715366B1 (en) * 2011-06-02 2017-07-19 Novartis AG Biomarkers for hedgehog inhibitor therapy
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013104104A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 诊断和预示乳腺癌的标志物
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
US20150252428A1 (en) * 2012-10-03 2015-09-10 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
HK1214633A1 (zh) * 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
MY180365A (en) * 2013-04-15 2020-11-28 Regeneron Pharma Markers of tumor cell response to anti-cancer therapy
CN103941016B (zh) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用
ES2820569T3 (es) * 2013-05-13 2021-04-21 Roussy Inst Gustave Biomarcadores de pronóstico y predictivos y aplicaciones biológicas de los mismos
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
WO2015077781A1 (en) * 2013-11-25 2015-05-28 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
KR20160097336A (ko) * 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
EP3090064B1 (en) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP4012049A3 (en) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to mek/erk inhibitors
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
WO2016011065A1 (en) * 2014-07-15 2016-01-21 Salk Institute For Biolofical Studies Detecting dixdc1 (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
CN104502603B (zh) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 Myo1d作为诊断动脉导管闭合或开放的标志物
CN105986023B (zh) * 2015-02-17 2021-01-05 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
WO2016131420A1 (zh) 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
CN105063183A (zh) * 2015-07-22 2015-11-18 浙江理工大学 泛素化途径相关基因在作为用于预测乳腺癌新辅助化疗疗效的生物标记物的应用
US20180231565A1 (en) * 2015-08-09 2018-08-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
US20180231561A1 (en) * 2015-08-12 2018-08-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105126080A (zh) * 2015-09-29 2015-12-09 武汉大学 锌指蛋白436（znf436）在治疗心肌肥厚中的应用
CN105671158B (zh) * 2016-02-29 2019-01-18 北京泱深生物信息技术有限公司 Fam63b基因在制备诊治子宫肌瘤的产品中的用途
AU2017249229A1 (en) * 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN105695617A (zh) * 2016-04-22 2016-06-22 王冬国 乳头状癌的肿瘤标志物及其应用
AU2017285350A1 (en) 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
US10519113B2 (en) * 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP2020514348A (ja) * 2017-03-15 2020-05-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライセオソーム変異及びその使用
CN109081866B (zh) * 2017-06-13 2021-07-16 北京大学 癌症中的t细胞亚群及其特征基因
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
KR20200030594A (ko) 2017-10-16 2020-03-20 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
CN109825508A (zh) * 2017-11-23 2019-05-31 深圳市第三人民医院 一种用来评估艾滋病合并结核感染的生物标记物
CN109870576B (zh) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用
US12054558B2 (en) * 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
CN108676867B (zh) * 2018-06-06 2020-06-09 青岛泱深生物医药有限公司 诊治子痫前期的vwce基因及其应用
CN108624678B (zh) * 2018-06-26 2020-07-17 青岛泱深生物医药有限公司 一种用于子痫前期诊治的生物标志物
CN108841960B (zh) * 2018-07-12 2022-02-01 吉林大学 一种结肠腺癌易感性预测试剂盒及系统
CN109468320A (zh) * 2018-11-13 2019-03-15 复旦大学附属中山医院 一种环状rna及其在肝癌诊断中的应用
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN111467493A (zh) * 2019-01-23 2020-07-31 首都师范大学 人rev3l蛋白切割抑制剂及其应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
JP2022543722A (ja) * 2019-08-16 2022-10-14 センター フォー エクセレンス イン ブレイン サイエンス アンド インテリジェンス テクノロジー，チャイニーズ アカデミー オブ サイエンシーズ 機能的ニューロン死に関連する神経系疾患の予防および／または治療におけるＰｔｂｐ１阻害剤の使用
CN110551819B (zh) * 2019-08-23 2023-05-16 伯克利南京医学研究有限责任公司 一组卵巢癌预后相关基因的应用
CN110408706B (zh) * 2019-08-30 2023-04-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种评估鼻咽癌复发的生物标志物及其应用
CN110643571B (zh) * 2019-10-22 2021-07-27 康妍葆(北京)干细胞科技有限公司 人角蛋白6a在干细胞培养中的应用及产品
KR102261606B1 (ko) * 2019-11-07 2021-06-07 (주)지노믹트리 대장암 검출 방법
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
CA3185499A1 (en) * 2020-06-09 2021-12-16 Genethon Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN113943798B (zh) * 2020-07-16 2023-10-27 中国农业大学 一种circ RNA作为肝细胞癌诊断标志物及治疗靶点的应用
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
CN112816708B (zh) * 2021-02-02 2022-05-31 中南大学湘雅二医院 一种预测食管鳞癌患者对化疗药物敏感性的蛋白指标及应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN112816711B (zh) * 2021-03-17 2024-04-19 中国医科大学附属盛京医院 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用
CN113373220A (zh) * 2021-05-08 2021-09-10 首都医科大学 与非小细胞肺癌预后相关的标志分子
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
CN113866424A (zh) * 2021-09-14 2021-12-31 哈尔滨医科大学 碳酸酐酶1和酸性鞘磷脂酶样磷酸二酯酶3a作为分子标志物在结直肠癌诊断中的应用
TWI817224B (zh) * 2021-10-26 2023-10-01 國立清華大學 用於預測乳癌預後情形的方法及套組
CN113897437B (zh) * 2021-11-30 2024-06-04 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于诊断乳腺癌的试剂盒中的应用
CN114592059A (zh) * 2022-01-11 2022-06-07 南方医科大学南方医院 一种评估5-fu治疗敏感性/耐药性的试剂盒
CN114525342B (zh) * 2022-03-03 2025-02-14 温州医科大学附属第一医院 Linc02806在肝细胞癌诊断和治疗中的应用
CN117813305A (zh) * 2022-03-16 2024-04-02 南京施江医药科技有限公司 一种含氮杂环类化合物及其用途
CN114672551B (zh) * 2022-05-17 2023-03-31 中国医科大学附属第一医院 Mat2a和mat2b作为检测或治疗良性前列腺增生的药物靶点的应用
CN115389764A (zh) * 2022-07-28 2022-11-25 宁波大学 蛋白质fbxo7在制备子宫内膜癌诊断标志物中的应用
CN115948529A (zh) * 2022-08-01 2023-04-11 湖南家辉生物技术有限公司 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用
CN116179691A (zh) * 2022-09-07 2023-05-30 苏州大学附属第一医院 一种胃癌组合标志物及标志物模型的建立方法
WO2024107924A2 (en) * 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System A blood-based lipid biomarker panel for personalized risk assessment of breast cancer
CN115948537B (zh) * 2022-12-19 2024-04-09 湖南家辉生物技术有限公司 一种基因chst3复合杂合突变的应用及检测试剂和应用
CN116287253B (zh) * 2023-02-22 2024-06-28 武汉科技大学 一种肺癌分子标志物及其应用
CN116500266B (zh) * 2023-03-07 2025-06-17 南通大学附属医院 MRPS21基因及其RNAi干扰系统的应用
CN116430048B (zh) * 2023-03-07 2025-06-20 南通大学附属医院 BTF3L4基因及其RNAi干扰系统的应用
CN117100866B (zh) * 2023-03-31 2025-10-28 兰州大学第二医院 一种抗肿瘤血管生成药物增效剂、抗肿瘤药物组合物及应用
CN116769916B (zh) * 2023-06-27 2025-03-07 南通大学附属医院 Tmed8基因在制备胰腺癌药物及其诊断试剂盒中的应用
CN116747215A (zh) * 2023-07-14 2023-09-15 新疆医科大学第三附属医院 V-9302在抑制肝癌和增强索拉菲尼抑癌作用中的应用
CN117257919B (zh) * 2023-11-10 2024-10-01 南通大学附属医院 Tbc1d15在筛选或制备保护肝脏的药物中的应用
CN117821469B (zh) * 2023-11-22 2024-08-02 扬州大学 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用
CN118045083B (zh) * 2024-04-15 2024-06-18 哈尔滨医科大学 L-脯氨酸在制备防治非酒精性脂肪肝病药物中的新用途
CN118879858B (zh) * 2024-06-27 2025-09-30 中国科学院合肥物质科学研究院 一组用于预测非小细胞肺癌放疗预后的基因标签及应用
CN120636556B (zh) * 2025-05-07 2026-06-16 武汉科技大学 一种筛选转录调控元件的方法及其应用
CN120442707B (zh) * 2025-07-14 2025-09-09 三亚中国农业科学院国家南繁研究院 棉花耐旱性和耐低温性相关蛋白GhCOX11及其应用
CN121559090B (zh) * 2026-01-08 2026-04-17 山东大学 完全性葡萄胎的生物标志物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
IL127210A0 (en) * 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US20040018570A1 (en) * 1999-09-01 2004-01-29 Brown University Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
CA2475206A1 (en) * 2002-02-15 2003-08-15 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US20040121375A1 (en) * 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion

Also Published As

Publication number Publication date
CA2662508A1 (en) 2008-07-10
EP2074226A2 (en) 2009-07-01
US20100004253A1 (en) 2010-01-07
AU2007340265B2 (en) 2012-07-26
WO2008082730A2 (en) 2008-07-10
RU2009114745A (ru) 2010-10-27
JP2013128487A (ja) 2013-07-04
CN101541977A (zh) 2009-09-23
JP2010504530A (ja) 2010-02-12
WO2008082730A3 (en) 2009-01-08
BRPI0716944A2 (pt) 2013-09-17
SG174826A1 (en) 2011-10-28
IL197450A0 (en) 2009-12-24
MX2009002936A (es) 2009-04-01
AU2007340265A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US20100004253A1 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
JP6290237B2 (ja) 癌を処置するための組成物および方法
WO2007067968A2 (en) Effects of inhibitors of fgfr3 on gene transcription
CN101999002A (zh) 诊断和治疗parp-介导的疾病的方法
JP2017517520A (ja) Ｗｅｅ１阻害剤を用いた癌を処置する方法
EP2972372B1 (en) Markers associated with wnt inhibitors
US12325880B2 (en) Identification of PDE3 modulator responsive cancers
JP2014221063A (ja) Ｂｒａｆバイオマーカー
CN108026588A (zh) Fgfr表达以及对fgfr抑制剂的敏感性
CA3166386A1 (en) Treatment of cancer with cdk12/13 inhibitors
TW201726140A (zh) 治療癌症之新型生物標記及方法
WO2014197411A1 (en) Compositions and methods for treating cancer
CN104968323A (zh) Crl4泛素连接酶抑制剂及其用途
Zhao et al. Role of ENPP1 in cancer pathogenesis: Mechanisms and clinical implications
US20230160016A1 (en) Methods of selecting a treatment for cancer patients
WO2025217307A9 (en) Methods for predicting response to a ras(on) inhibitor and combination therapies
Zhao et al. Expression of somatostatin and its receptor 1‑5 in endometriotic tissues and cells
Litovkin et al. Microarray study of gene expression in uterine leiomyoma
US12560609B2 (en) Biomarkers predictive of cancer cell response to ML329 or a derivative thereof
CN1626679A (zh) 评估和治疗癌症的方法
WO2007022041A2 (en) Mutations and polymorphisms of hdac3
AU2010336257A1 (en) Method for Predicting Therapeutic Effects of Chemotherapy on Hepatocellular Carcinoma Patients
HK40081065A (en) Treatment of cancer with cdk12/13 inhibitors
HK1154405A (en) Methods of diagnosing and treating parp-mediated diseases
HK1212771B (en) Markers associated with wnt inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000